Company intelligence / Profile preview

Patch Biosciences

New York, New York, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Patch Biosciences was a New York-based biotechnology company that built an AI platform for sequence design to enable effective, specific, and durable genetic medicines. Its core technologies focused on AI/ML-based design for synthetic promoters and RNA UTRs to accelerate gene and RNA therapeutic programs. The company did not have a traditional drug pipeline or clinical-stage assets, and its technologies were integrated into Ginkgo Bioworks after its acquisition in February 2024.

Modalities: Gene therapyRNA therapy
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Patch Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Patch Biosciences.

Explore the full profile